Weight loss & metabolic health

Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and weight management (Ozempic, Wegovy). Taken once a week.

How it works

A GLP-1 agonist: it releases insulin when blood sugar is high, lowers glucagon, slows down the stomach and acts on the brain’s appetite centers.

What it is used for

Type 2 diabetes (Ozempic), long-term weight management (Wegovy) and lowering cardiovascular risk.

What the evidence says

In the STEP trials, people lost about 15% of their weight in 68 weeks. The SELECT trial showed 20% fewer heart attacks and strokes in people with obesity.

Side effects and cautions

Nausea, vomiting, diarrhea and constipation are common. Gallbladder problems and pancreatitis are possible. Not for people with a history of medullary thyroid cancer or MEN2. Some muscle is lost along with fat, and weight usually returns after stopping.

Half-life

About 1 week (label)

Makes sense for

  • Adults with obesity, or overweight with a weight-related condition
  • Type 2 diabetes

Does not make sense for

  • Type 1 diabetes
  • A history of pancreatitis
  • Medullary thyroid cancer or MEN2
  • People at a healthy weight

Boost the effect

  • High-protein meals (about 1.2–1.6 g per kg of body weight a day): help keep muscle while you lose weight
  • Strength training 2–3 times a week: protects muscle and strength
  • Plenty of water and fiber: ease the usual constipation and nausea